Stereotaxis launches Synchrony system following FDA 510(k) clearance
Compartilhar
Stereotaxis (NYSE:STXS), a pioneer in innovative robotic technologies for the treatment of cardiac arrhythmias, announced on April 6, 2026, that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Synchrony™ interventional lab display system.
